Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called abatacept, given by injection under the skin (subcutaneous), in people with rheumatoid arthritis. A total of 100 people took part in the main four-month study — 51 in a group receiving abatacept together with another medicine called methotrexate, and 49 in a group receiving abatacept on its own. A separate longer-term follow-up phase then enrolled 90 participants. The main thing the trial was measuring was whether participants developed antibodies against the abatacept medication itself — in other words, whether the body's immune system started to recognise and react to the drug. The trial also tracked a disease activity score called DAS28-CRP, which is a combined measure of joint tenderness, joint swelling, a blood inflammation marker, and the participant's own rating of their condition, all rolled into a single number. The reported data shows that, when tested using the standard laboratory method (ELISA) at the end of the four-month study, zero participants in either group were found to have developed detectable antibodies against abatacept. When a more sensitive laboratory method (ECL/MSD) was used across the same period, only one participant in the combination group showed a positive antibody result at any point, while zero in the monotherapy group did across most time points. For the disease activity score, the reported data shows an average decrease (improvement) of 1.67 points in the combination group and 1.94 points in the monotherapy group from their starting scores to the end of the four months. For two of the primary outcome measures relating to antibody responses in subgroups, no numerical data was reported on ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 23097311) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Rheumatoid Arthritis by a doctor
- You rate your overall disease condition as at least 20 out of 100 on a simple sliding scale measurement
- You are willing and able to stop taking all biological treatments and most other arthritis medications, except for methotrexate, which you may continue
Who may not be able to join:
- You have previously been treated with a medication called rituximab
- You have previously been treated with any of the following: immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (also known as Cellcept®), cyclosporine A, other similar immune-suppressing drugs known as calcineurin inhibitors, or D-Penicillamine
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study; Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (ELISA Method) Over Time During the ST Study; Number of Participants With Positive Anti-abatacept Responses to Abatacept (Meso-Scale Discovery [MSD] Electrochemiluminescence [ECL] Assay Method) Over Time During the ST Study; Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for ELISA Results); Immunogenicity in MTX Naive and MTX-previous Us...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.